CA2758823A1 - Protein phosphatase 2a-activating agents - Google Patents

Protein phosphatase 2a-activating agents Download PDF

Info

Publication number
CA2758823A1
CA2758823A1 CA2758823A CA2758823A CA2758823A1 CA 2758823 A1 CA2758823 A1 CA 2758823A1 CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A CA2758823 A CA 2758823A CA 2758823 A1 CA2758823 A1 CA 2758823A1
Authority
CA
Canada
Prior art keywords
chroman
enyl
yloxy
dimethyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2758823A
Other languages
English (en)
French (fr)
Inventor
Ching-Shih Chen
Dasheng Wang
Samuel K. Kulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CA2758823A1 publication Critical patent/CA2758823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
CA2758823A 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents Abandoned CA2758823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16875909P 2009-04-13 2009-04-13
US61/168,759 2009-04-13
PCT/US2010/030799 WO2010120711A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Publications (1)

Publication Number Publication Date
CA2758823A1 true CA2758823A1 (en) 2010-10-21

Family

ID=42981438

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2758823A Abandoned CA2758823A1 (en) 2009-04-13 2010-04-13 Protein phosphatase 2a-activating agents

Country Status (6)

Country Link
US (1) US8461362B2 (enExample)
EP (1) EP2419414A4 (enExample)
JP (1) JP2012523458A (enExample)
AU (1) AU2010236655A1 (enExample)
CA (1) CA2758823A1 (enExample)
WO (1) WO2010120711A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
US9220706B2 (en) 2012-06-01 2015-12-29 National Institutes Of Health (Nih) Inhibition of leukemic stem cells by PP2A activating agents
JP6757730B2 (ja) * 2014-12-31 2020-09-23 フリューダイム カナダ インコーポレイテッド マスサイトメトリーによる分析用の構造化生体試料
CN108779073A (zh) * 2015-06-23 2018-11-09 凯斯西储大学 用于治疗癌症的组合物和方法
BR112018002550A2 (en) 2015-08-10 2018-09-18 Dana-Farber Cancer Institute, Inc. inhibitor resistance mechanism

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2680749A (en) * 1951-12-01 1954-06-08 Eastman Kodak Co Water-soluble tocopherol derivatives
DE2822324C3 (de) * 1978-05-22 1981-02-26 Basf Ag, 6700 Ludwigshafen Herstellung von Vitamin-E-Trockenpulver
JPS59222415A (ja) 1983-05-31 1984-12-14 Kuraray Co Ltd 免疫調節剤
US4751224A (en) * 1983-07-21 1988-06-14 Brown University Research Foundation Treatment of metastasis
WO1997024112A1 (en) * 1995-12-28 1997-07-10 Yoshitomi Pharmaceutical Industries, Ltd. External preparation
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
IL142082A (en) * 1998-09-23 2005-12-18 Res Dev Tocoflowers, tocotrinols, derivatives as a novel and other side-chain and their uses
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
JP2002121132A (ja) * 2000-08-09 2002-04-23 Showa Denko Kk 発がん抑制剤および発がん抑制方法
US20040248971A1 (en) * 2001-07-27 2004-12-09 Shuyuan Yeh Use of vitamin e succinate and antiandrogen combination
US6858227B1 (en) * 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20050215531A1 (en) * 2002-05-16 2005-09-29 Thomas Baumruker Use of edg receptor binding agents in cancer
WO2005025553A2 (en) * 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
RU2433117C2 (ru) * 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
AU2007217810B2 (en) * 2006-02-21 2012-10-11 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
BRPI0715950A2 (pt) 2006-08-17 2013-07-30 Univ Chicago tratamento de doenÇas inflamatàrias
CA2663474C (en) * 2006-09-15 2017-06-27 Griffith University Pro-oxidant anti-cancer compounds
JP4481316B2 (ja) * 2007-01-09 2010-06-16 株式会社エヌ・ティ・ティ・ドコモ ユーザ装置および送信方法
BRPI0813683A2 (pt) * 2007-06-14 2019-09-24 Mitsubishi Tanabe Pharma Corp composto amina e uso farmacêutico do mesmo
CA2739901A1 (en) 2008-10-17 2010-04-22 Akaal Pharma Pty Ltd S1p receptors modulators
JP2012523458A (ja) 2009-04-13 2012-10-04 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション タンパク質ホスファターゼ2a活性化剤
CA2759011A1 (en) * 2009-04-17 2010-10-21 The Ohio State University Research Foundation Antiadhesion agents

Also Published As

Publication number Publication date
EP2419414A1 (en) 2012-02-22
JP2012523458A (ja) 2012-10-04
US8461362B2 (en) 2013-06-11
AU2010236655A1 (en) 2011-11-17
US20100267673A1 (en) 2010-10-21
WO2010120711A1 (en) 2010-10-21
EP2419414A4 (en) 2013-12-04

Similar Documents

Publication Publication Date Title
US8461362B2 (en) Protein phosphatase 2A-activating agents
Yan et al. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo
Nambiar et al. Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1
Johnson et al. Apoptosis signaling pathways mediated by cyclooxygenase-2 inhibitors in prostate cancer cells
US9757350B2 (en) Small molecule inhibitors of replication protein A that also act synergistically with cisplatin
AU2015314772A1 (en) Compositions and methods for treatment of prostate carcinoma
Wang et al. Inhibition of heat shock induction of heat shock protein 70 and enhancement of heat shock protein 27 phosphorylation by quercetin derivatives
CN107921015A (zh) 具有脂肪组织甘油三酯降解作用的壬二酸组合物
US7026346B2 (en) Compounds and methods for inducing apoptosis in proliferating cells
EP2418948B1 (en) Antiadhesion agents
Yang et al. Isowalsuranolide targets TrxR1/2 and triggers lysosomal biogenesis and autophagy via the p53-TFEB/TFE3 axis
WO2012087889A2 (en) Dna methylation inhibitors
Hernández‐Velázquez et al. Multidrug resistance reversed by maleimide interactions. A biological and synthetic overview for an emerging field
AU2007217810B2 (en) Anticancer agents
JP2013507397A (ja) チアゾリジンジオンエネルギー制限模倣剤
US10188743B2 (en) Cytisine-linked isoflavonoid antineoplastic agents for the treatment of cancer
US8519007B2 (en) Use certain diterpene compounds in the treatment of androgen receptor-associated diseases
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
KR101207981B1 (ko) 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법
WO2016160819A1 (en) Method for the treatment of nf1-or ras-associated disorders
US20140031388A1 (en) Akt inactivation by tocopheryl derivatives
US20060142368A1 (en) Compounds and methods for inducing apoptosis in proliferating cells
Estévez Braun et al. 1, 2, 3-Triazole-totarol conjugates as potent PIP5K1α lipid kinase inhibitors
Viehoever et al. Therapeutic interference of SREBP-mediated lipid metabolism by E-Xanthohumol attenuates prostate cancer progression
US9156790B2 (en) Anticancer P21-activated kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160413